Loading…
Chemomab Therapeutics Ltd. is projected to rise to $2.55 by 2027, a +34% move from its current price of $1.90. CMMB is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.82 | $1.90 | $1.99 | +0.15% |
| May 30 | $1.79 | $1.91 | $2.02 | +0.30% |
| May 31 | $1.77 | $1.91 | $2.05 | +0.45% |
| Jun 1 | $1.76 | $1.91 | $2.08 | +0.60% |
| Jun 2 | $1.74 | $1.91 | $2.10 | +0.75% |
| Jun 3 | $1.73 | $1.92 | $2.13 | +0.90% |
| Jun 4 | $1.72 | $1.92 | $2.15 | +1.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.72 | $1.92 | $2.15 | +1.05% |
| Week 2 | $1.66 | $1.94 | $2.27 | +2.12% |
| Week 3 | $1.61 | $1.96 | $2.38 | +3.20% |
| Week 4 | $1.58 | $1.98 | $2.48 | +4.29% |
| Week 5 | $1.56 | $2.00 | $2.57 | +5.39% |
| Week 6 | $1.54 | $2.02 | $2.66 | +6.50% |
| Week 7 | $1.52 | $2.04 | $2.75 | +7.62% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Chemomab Therapeutics Ltd. (CMMB) is currently priced at $2.02 per share and has a market cap of $14.54M, with a rank of 5043. These figures place the stock among smaller-cap biotech peers and reflect its clinical-stage status within the healthcare sector.
Technically, the sentiment is BULLISH. The RSI(14) is 70, with a simple moving average of $1.69 for the 50-day period and $2.28 for the 200-day period. Near-term support sits at $1.46 and resistance at $2.02. The stock has traded within a 30-day range of $1.52 to $2.68 and exhibits an annualized volatility of 80%.
Forecast-wise, the 2026 path shows a min of $1.44, an avg of $2.02, and a max of $3.10 with ROI of 0 and sentiment NEUTRAL. The subsequent years display bull-leaning momentum, culminating in a 2050 forecast with an avg of $16.30 and a max of $36.55, representing a 707% ROI and a bullish sentiment.
A major floor 35.4% below — a decisive break under it would weaken the trend.
The nearest floor, 23.2% below — buyers have tended to step in here.
The nearest ceiling, 6.8% above — a clean break opens room to run.
A major ceiling 24.6% above — clearing it would confirm fresh momentum.
Key CMMB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CMMB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.89 | Buy | $1.89 | Buy |
| MA 10 | $1.77 | Buy | $1.82 | Buy |
| MA 20 | $1.72 | Buy | $1.76 | Buy |
| MA 50 | $1.69 | Buy | $1.72 | Buy |
| MA 100 | $1.70 | Buy | $1.86 | Buy |
| MA 200 | $2.26 | Sell | $2.42 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.80 | Neutral |
| Stoch RSI (14) | 66.92 | Neutral |
| CCI (20) | 99.01 | Neutral |
| Williams %R (14) | -27.08 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 7.34 | Buy |
| Bollinger %B (20,2) | 0.80 | Neutral |
| Stochastic %K (14) | 72.92 | Neutral |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | 0.20 | Buy |
| Ultimate (7,14,28) | 62.03 | Neutral |
| Momentum (10) | 0.13 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 2.05 | Sell |
| ADX (14) | 15.03 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture leans bullish with RSI(14) at 70, indicating strong momentum but potential overbought conditions. The stock trades above its near-term support level and remains near resistance at $2.02, with SMA50 at $1.69 and SMA200 at $2.28 providing context for the longer trend.
The 30-day price range spans $1.52 to $2.68, highlighting the current volatility in this micro-cap biotech name. The combination of a bullish technical tone and a tight 30-day band suggests upside potential but also considerable risk given the low market capitalization and high volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.44 | $1.90 | $2.90 | 0% | Neutral | |
| $1.91 | $2.55 | $3.65 | +34% | Bullish | |
| $1.79 | $2.50 | $3.76 | +31% | Bullish | |
| $1.83 | $2.64 | $4.15 | +39% | Bullish | |
| $1.78 | $2.67 | $4.33 | +41% | Bullish | |
| $2.03 | $3.13 | $5.24 | +65% | Bullish | |
| $2.69 | $4.29 | $7.35 | +126% | Bullish | |
| $2.76 | $4.53 | $7.96 | +139% | Bullish | |
| $2.63 | $4.43 | $7.95 | +133% | Bullish | |
| $2.46 | $4.26 | $7.80 | +124% | Bullish | |
| $3.78 | $7.43 | $14.74 | +291% | Bullish | |
| $6.70 | $14.89 | $33.23 | +684% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.44 | $1.90 | $2.27 | +0.00% |
| June 2026 | $1.76 | $2.09 | $2.57 | +10.20% |
| July 2026 | $1.81 | $2.18 | $2.72 | +4.04% |
| August 2026 | $1.78 | $2.17 | $2.76 | -0.42% |
| September 2026 | $1.84 | $2.26 | $2.90 | +3.97% |
| October 2026 | $1.89 | $2.34 | $3.05 | +3.75% |
| November 2026 | $1.81 | $2.26 | $2.97 | -3.42% |
| December 2026 | $1.74 | $2.19 | $2.90 | -3.20% |
Click any year to see its month-by-month CMMB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CMMB to range from $1.44 to $2.90 through 2026. The $1.90 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CMMB price prediction for 2027 points to an average of $2.55 (low $1.91, high $3.65) — a potential gain of +34% on today's $1.90. Buyers look set to stay in control over this stretch.
In 2028, CMMB is projected to trade between $1.79 and $3.76, averaging $2.50 — a potential gain of +31% from today's $1.90. That is -2% versus the projected 2027 average. Momentum favours further upside here.
Chemomab Therapeutics Ltd.'s 2029 outlook centres on $2.64, within a $1.83 to $4.15 range. That is up +6% on the projected 2028 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CMMB could reach as high as $4.33, with a base case around $2.67 and support toward $1.78 — roughly +41% from $1.90. Momentum favours further upside here.
Expect CMMB to range from $2.03 to $5.24 through 2031. The $3.13 average target implies a +65% move from current prices. That is up +17% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CMMB price prediction for 2032 points to an average of $4.29 (low $2.69, high $7.35) — a potential gain of +126% on today's $1.90. Momentum favours further upside here.
In 2033, CMMB is projected to trade between $2.76 and $7.96, averaging $4.53 — a potential gain of +139% from today's $1.90. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Chemomab Therapeutics Ltd.'s 2034 outlook centres on $4.43, within a $2.63 to $7.95 range. That is -2% versus the projected 2033 average. That marks a +133% change versus current levels. Momentum favours further upside here.
By 2035, CMMB could reach as high as $7.80, with a base case around $4.26 and support toward $2.46 — roughly +124% from $1.90. Buyers look set to stay in control over this stretch.
Expect CMMB to range from $3.78 to $14.74 through 2040. The $7.43 average target implies a +291% move from current prices. That is up +74% on the projected 2035 average. Momentum favours further upside here.
The CMMB price prediction for 2050 points to an average of $14.89 (low $6.70, high $33.23) — a potential gain of +684% on today's $1.90. Buyers look set to stay in control over this stretch.
Investing $1,000 in CMMB today (≈ 526.315789 CMMB) could be worth
$7,839.43
+$6,839.43 (+684%) by 2050 · US Dollar
Based on the average projected CMMB price of $14.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CMMBwould be worth at today's price.
$1,000 invested in CMMB on May 27, 2025 (≈ 178.571432 CMMB) would be worth
$339.29
-$660.71 (-66.1%) today · 0.34× · US Dollar
Based on a CMMB entry price of $5.6 vs. today's $1.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.66 | $1,144.58 | +14.5% |
| 1 month ago | $1.54 | $1,233.77 | +23.4% |
| 3 months ago | $1.55 | $1,225.81 | +22.6% |
| 6 months ago | $2.62 | $725.19 | -27.5% |
| 1 year ago | $5.6 | $339.29 | -66.1% |
| All time (5.0y) ago | $68.24 | $27.84 | -97.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CMMB forecast.
Our base-case forecast reaches $3.80 around 2032.
Implied market cap at $3.80: $27.36M
The multi-year forecast shows a clearly bullish tilt after 2026, with steadily higher average prices and expanding upside potential. By 2030 the avg price is projected at $2.88 with a 42.4% ROI, reinforcing a positive longer-term trajectory despite the 2026 flat ROI. The outlook strengthens further into the 2030s, with 2032 and 2033 showing annual avg prices of $4.66 and $4.90 and ROI of 130.8% and 142.8%, respectively.
By 2040, the forecast envisions an avg price of $8.01 and a max of $15.97, representing a 296.5% ROI and continuing bullish sentiment. The glow of upside extends to 2050, with an avg price of $16.30 and a max of $36.55, delivering a 707% ROI and a firmly bullish stance.
These numbers imply meaningful upside in the long run while acknowledging the inherent uncertainties of clinical-stage biotechnology. The forecasts are estimates and are not guaranteed, and actual results depend on development milestones, regulatory outcomes, and market dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $2.88 with a min of $1.91 and a max of $4.68, and a ROI of 42.4%. The sentiment is bullish.
The forecast shows bullish sentiment from 2027 onward, with rising avg prices and higher ROI: 2027 avg $2.73 ROI 35.3%, 2032 ROI 130.8%, and 2050 ROI 707%. Note that 2026 has a neutral outlook and ROI of 0%.
Yes. The 2040 forecast lists a max price of $15.97, confirming that the stock could exceed $10 by 2040.
Current price is $2.02 and market cap is $14.54M.
The 30-day range is $1.52 to $2.68, and the RSI(14) is 70.
Chemomab Therapeutics Ltd. Community Discussion
0Share your Chemomab Therapeutics Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.